Showing papers in "Value in Health in 2012"

TL;DR: The nonparametric model was preferred for its simplicity while performing similarly to the other models, and being independent of the value set that is used, it can be applied to transform any EQ-5D-3L value set into EQ- 5D-5L index values.

TL;DR: Best practice recommendations for state-transition modeling are provided, directed both to modelers and to users of modeling results such as clinicians, clinical guideline developers, manufacturers, or policymakers.

TL;DR: The article argues that the estimation of point estimates and uncertainty in parameters is part of a single process and explores the link between parameter uncertainty through to decision uncertainty and the relationship to value of information analysis.

TL;DR: Recommendations for achieving transparency and validation developed by a taskforce appointed by the International Society for Pharmacoeconomics and Outcomes Research and the Society for Medical Decision Making are described.

TL;DR: In this paper, the authors present the updated recommendations for best practices in conceptualizing models; implementing state-transition approaches, discrete event simulations, or dynamic transmission models; and dealing with uncertainty and validating and reporting models transparently.

TL;DR: In this paper, the authors provide consensus-based guidelines for the application of state-transition models in the context of health care, and provide best practice recommendations for state transition modeling.

TL;DR: The development of models whose purpose is to inform medical decisions and health-related resource allocation questions is considered, and best practices relating to the specific characteristics of model structure and which characteristics of the problem might be most easily represented in a specific modeling method are presented.

TL;DR: It is shown how incorporating individual patient data from trials of one treatment into indirect comparisons can address several limitations that arise in analyses based only on aggregate data and reduce observed cross-trial differences in the selected examples.

TL;DR: In this paper, a review of state-of-the-art methods for incorporating multiple criteria in health technology assessment is provided and compared with the current UK National Institute for Health and Clinical Excellence health technology appraisal process.

TL;DR: The EUROHIS-QOL 8-item index showed acceptable cross-cultural performance and a satisfactory discriminant validity and would be a useful measure to include in studies to assess treatment effectiveness.

TL;DR: This report details the recommendations of a Good Research Practice Task Force on Prospective Observational Studies for comparative effectiveness research and summarizes the challenges and approaches to the appropriate design, analysis, and execution of prospective observational studies to make them most valuable and relevant to health-care decision makers.

TL;DR: The aim of this article was to provide consensus-based guidelines on the application of DES in a health care setting, covering the range of issues to which DES can be applied.

TL;DR: Substantial savings could be achieved by switching private sector purchases from originator brand medicines to lowest-priced generic equivalents and strategies to promote generic uptake, such as generic substitution by pharmacists and increasing confidence in generics by professionals and the public should be included in national medicines policies.

TL;DR: A statistical model is developed that incorporates an adjusted limited dependent variable approach to reflect the upper bound and the large gap in feasible EQ-5D questionnaire values and demonstrated superior performance in a rheumatoid arthritis setting.

TL;DR: In this article, the authors compared the CHU9D and KIDSCREEN-10, a short generic measure for assessing children and adolescents' health-related quality of life and well-being.

TL;DR: Five key areas in which health economics and outcomes research best practices could be developed to improve value assessment, reimbursement, and patient access decisions for personalized medicine have been identified.

TL;DR: It is possible that the early identification and treatment of fatigue and mental health symptoms may improve productivity while working and extend employment for individuals with MS.

TL;DR: Direct costs of ICU days vary widely between the seven departments, and the standardized costing methodology could serve as a valuable instrument to compare actual cost differences, such as those resulting from differences in patient case-mix.

TL;DR: A range of decision options may facilitate paying for the use of promising medical technologies despite their uncertain evidence, and it is important that the option be chosen on the basis of not only the expected value of a technology but also the value of furtherResearch, the anticipated effect of coverage on further research, and the costs associated with reversing the decision.

TL;DR: The development of a reference case for including informal care; sensitivity analysis for contentious issues; and a statement for the reason for excluding informal care may help to improve the way that informal care is included in economic evaluations in the future.

TL;DR: The EQ-5D health-related assessment instrument's performance differed according to condition, with poor performance in age-related macular degeneration (AMD) and diabetic retinopathy, and the HUI-3 seemed to perform better in some conditions, but the evidence on this and SF-6D is limited.

TL;DR: The FDA continues to approve PRO claims, with 24% of new molecular entities and biologic license applications being granted after the release of the US Food and Drug Administration (FDA) draft PRO guidance.

TL;DR: The application of multicriteria decision analysis (MCDA) to guide the coverage decisions on including health interventions in the Universal Coverage Scheme health benefit package in the period 2009-2010 has considerably contributed to the rational, transparent, and fair priority-setting process through the application of MCDA.

TL;DR: The FACT-Leu scale is a valid, reliable, and efficient measure of leukemia-specific health-related quality of life for acute and chronic disease.

TL;DR: AF-related medical costs are high, reflecting resource-intensive and long-term treatments including anticoagulation treatment, and justify increased attention to the management of patients with AF.

TL;DR: The introduction of PBMs that are specific to a certain disease may have the merit of sensitivity to disease-specific effects of interventions, but that gain is traded off to the loss of comparability of utility values and, in some cases, insensitivity to side effects and comorbidity.

TL;DR: These emergent effects of orphan drug policies raise doubts about the equity of access to drugs, they highlight the limitations of the cohort paradigm in medicine, and they force third-party payers to make drugs accessible even when the prices of drugs are believed to be disproportionate to the clinical effects obtained.

TL;DR: Preference-based single index measures from DEMQOL andDEMQOL-Proxy for use in economic evaluation will enable economic evaluation using quality-adjusted life-years to be undertaken for people across the full range of dementia severity.

TL;DR: There is only limited evidence for the cost-effectiveness of conservative treatments for the management of hip and/or knee osteoarthritis, and more high-quality economic evaluations of conservative interventions are needed to further inform practice.